Lowered adiponectin levels, especially in post-menopause and in obesity, represent weaker defenses against the development of EC; obesity's adverse effects on adiponectin concentration would only amplify this condition. This evidence concerns the gene ADIPOQ and obesity due to melanocortin 4 receptor deficiency.